Methods: PROMs data was collected from all patients visiting one of the outpatient rheumatology clinics at the University of Michigan from July 1, 2016 – Jan 31, 2017. An Android based tablet using Welcome[®] software was handed to every patient with instructions to complete a questionnaire on Adult Physical Function and Pain Intensity Score – PROMIS based questionnaires on patient-reported outcome measures. The results were stored in the patients EMR.

Results: Between July 1st 2016 and Jan 31st, 2017, we collected PROMs on patients via patient portals (home computers) and in office mobile devices-tablets. Assisted completion was done by clinic staff on a clinic desk top computer. Total of 2059 out of 2554 patients invited to participate completed the PROMs questionnaires. Of those patients that answered the questionnaires, 82% were done on a mobile device, 10% of patients used the home portal, 8% of patients needed in office assistance. 20% of patients did not answer the questionnaires.

Mode for completion of PROMs	Number of patients
Mobile Device	1694
Portal Home PC	211
Assisted in clinic	154
Total questionnaires completed	2059

Conclusions: Mobile devices are being increasingly used by the patients in the United States for capture of PROMs. Mobile devices increased the PROMs collection rate from approximately 10% to 80% when combining both home portal (home PC) and an office based mobile device (Tablet). Mobile devices alone accounted for >80% of the collection rate of PROMs. In an era of changing information technology, the utilization of mobile devices for PROMs should be explored as a preferred modality.

References:

- [1] Wagner L, et al. Integrating the Patient-Reported Outcomes Measurement Information System (PROMIS) symptom assessment into routine cancer care. *Cancer* 2015 Mar 15;121(6):927–34.
- [2] <http://www.nihpromis.com/>.

Disclosure of Interest: V. Ognenovski: None declared, K. Burger: None declared, K. Weiss: None declared, L. Esser: None declared, D. Khanna Grant/research support from: Bayer, BMS, Genentech/Roche, Sanofi-Aventis, NIH K24AR063120, Consultant for: Actelion, Bayer, Covis, Cytori, EMD Serono, Genentech/Roche, Gilead, GSK, Sanofi-Aventis

DOI: 10.1136/annrheumdis-2017-eular.6300

Epidemiology, risk factors for disease or disease progression

AB1116 PREVALENCE OF POLIAUTOIMMUNITY AND FAMILY AUTOIMMUNITY IN MEXICO

A. Arellano-Martinez, V. Gonzalez-Diaz, S. Cerpa-Cruz, S. Gutierrez-Ureña, J. Reyes-Rueda, K. Garcia-Osuna, G.E. Martinez-Bonilla. *Rheumatology Service, Hospital Civil Fray Antonio Alcalde, Guadalajara, Mexico*

Background: Autoimmune diseases share pathophysiological mechanisms, genetic factors and certain environmental triggers. Its frequency is reported up to 43% for poliautoimmunity and almost half of these have family autoimmunity, but this is unknown in our population.

Objectives: To identify the prevalence of poliautoimmunity and family autoimmunity in a Rheumatology Service of a third level hospital in Mexico.

Methods: Observational, descriptive, cross-sectional study. Consecutive outpatients who attended the Rheumatology Service of the Hospital Civil de Guadalajara "Fray Antonio Alcalde" during 2 months were applied a questionnaire to obtain demographic data, autoimmunity and risk factors. Descriptive statistical analysis was done.

Results: Of 1,208 patients, 484 (40%) had autoimmunity, of these 58 (12%) had poliautoimmunity and 6 (1%) with Multiple Autoimmune Syndrome (MAS). The most frequent of 35 autoimmune diseases registered were: RA 42%; SLE 17%; AS 6%; SSC 5%; SSj 4%; PsA 3%; JIA 3%; autoimmune hypothyroidism 3%; APS 2%; Dermatomyositis 2% and Psoriasis 1%. In the group with poliautoimmunity SLE was present in 26 (45%) patients, SSj in 13 (22%) and autoimmune thyroid disease in 14 (24%). In the MAS group autoimmune thyroid disease in 5 patients. Patients with poliautoimmunity developed first: SLE (14%) and RA (14%). In the patient with MAS autoimmune thyroid disease in 33%. Of the 58 patients with poliautoimmunity 31 (53%) have familial autoimmunity, of which SLE is the most frequent in (22%), followed by autoimmune thyroid disease (17%) and RA (16%). All 6 MAS patients had familial autoimmunity. Referent to risk factors: 154/484 reported active smoking. Of the 58 patients with poliautoimmunity, only 23 (40%) had or are current smokers. Of the 6 patients with MAS 50% presented this risk factor. 158/484 (33%) patients had periodontal disease. In patients with autoimmune disease 54% were overweight (28%) or obese (26%). Of the 58 patients with poliautoimmunity 48% were overweight and 21% obese; of patients with MAS 50% were overweight or obese. Only one patient had ASIA syndrome with GCA diagnosed.

Conclusions: The search of poliautoimmunity is required in all patients with autoimmune disease and convenient to consider that these patients will have a

higher frequency for familial autoimmunity. Smoking and periodontal disease are widely known risk factors that are not taken seriously by patients.

References:

- [1] Raza KeGD. Preclinical Inflammatory Rheumatic Diseases. An Overview and Relevant Nomenclature. *Rheumatic Diseases Clinic of North America*. 2014;(40).
- [2] Coelho Aec. Familial autoimmunity and polyautoimmunity in 60 Brazilian Midwest patients with systemic sclerosis. *Revista Brasileira de Reumatologia*. 2016;; p. 314–22.
- [3] Anaya Jec. The kaleidoscope of autoimmunity: multiple autoimmune syndromes and familial autoimmunity. *Expert Review of Clinical Immunology*. 2007;; p. 623–35.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.6952

AB1117 LATENT TUBERCULOSIS INFECTION AND TUBERCULOSIS IN PATIENTS WITH RHEUMATIC DISEASES UNDER TREATMENT WITH ANTI-TUMOR NECROSIS FACTOR DRUGS

A.L.B. Morsch¹, G. Garziera², F. Otesbelgue³, F.L. Staub³, P.E. Palominos¹, C.V. Brenol^{1,3}, D.R. Silva^{2,3,4}. ¹Serviço de Reumatologia; ²Programa de Pós-Graduação em Ciências Pneumológicas, Hospital de Clínicas de Porto Alegre; ³Faculdade de Medicina, Universidade Federal do Rio Grande do Sul; ⁴Serviço de Pneumologia, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

Background: The introduction of biological agents, especially the tumor necrosis factor inhibitors (anti-TNF) for the treatment of rheumatic diseases increased the risk of developing tuberculosis (TB). Screening for latent TB infection (LTBI) is strongly recommended before starting therapy with anti-TNF agents.

Objectives: This study aimed to identify the prevalence of LTBI and TB among patients with rheumatic diseases on anti-TNF drugs.

Methods: In a cross-sectional study, the electronic medical records of all adult patients (≥18 years old) undergoing anti-TNF treatment at Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, were reviewed. Every patient underwent Tuberculin Skin Test (TST) before starting anti-TNF treatment.

Results: In total, 176 patients were included. The mean age was 51.9±12.4 years, 34.7% were males, and 90.9% were white. The underlying diseases were rheumatoid arthritis (RA) in 50.6% (N=89), ankylosing spondylitis (AS) in 27.8% (N=49) and psoriatic arthritis (PsA) in 17.6% (N=31). Anti-TNF agents started after TST were: infliximab (22.7%, N=40), adalimumab (48.9%, N=86), etanercept (27.3%, N=48), and golimumab (1.1%, N=2). The prevalence of positive TST was 29.5%. Household contact with TB was significantly associated with a positive TST (p=0.020). RA patients had lower TST reactions than AS patients (p=0.022). There were six cases of TB (3.4%) diagnosed during anti-TNF therapy.

Conclusions: We demonstrated a high prevalence of positive TST (29.5%) among patients with rheumatic diseases in a region with high TB prevalence. Our data corroborates the ACR's recommendation that patients who live in high TB incidence settings should be tested annually for LTBI.

References:

- [1] Ishiguro T, Takayanagi N, Kagiya N, Yanagisawa T, Sugita Y: Characteristics of tuberculosis in patients with rheumatoid arthritis: a retrospective single-center study. *Intern Med* 2014, 53: 1291–1298.
- [2] Arkema EV, Jonsson J, Baecklund E, Bruchfeld J, Feltelius N, Askling J: Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments? *Ann Rheum Dis* 2015, 74: 1212–1217.
- [3] Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM et al.: 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. *Arthritis Care Res (Hoboken)* 2012, 64: 625–639.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.6340

AB1118 REVIEW OF METHODS FOR ASSESSING THE RELATIONSHIP BETWEEN WEATHER AND CHRONIC MUSCULOSKELETAL PAIN

A. Beukenhorst¹, J. McBeth¹, D. Schultz², J. Sergeant^{1,3}, W.G. Dixon¹. ¹Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research; ²Centre for Atmospheric Science, School of Earth and Environmental Sciences, University of Manchester; ³NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom

Background: People with chronic pain commonly believe that their pain is affected by the weather. Despite a century's worth of research, there is no scientific consensus on the existence of a relationship between weather and chronic pain.

Objectives: A systematic literature review to (1) gain an overview of existing research on the weather-pain relationship, and (2) summarise the methodologies, methodological rigour and risk of bias in published studies of patients with musculoskeletal conditions.

Methods: Systematic search strategies were developed for 5 databases (Medline, Embase, PsycInfo, Scopus, Web of Science) to retrieve studies that investigated the relationship between weather conditions and chronic pain. Original articles describing observational studies that related chronic pain (primary outcome) to weather conditions (exposure), were included. Study characteristics, methodology (e.g. measurements of pain and weather, aspects of statistical analysis) and data on risk of bias (validation of participants' exposure and diagnosis, coverage of weather variation, correction for confounders) was extracted. Methodological rigour was summarised by mapping the methodological variability among studies and ranking these from least to most rigorous.

Results: The searches returned 16,081 articles. After removing 3090 duplicates and excluding 12726 articles during title screening, 265 abstracts were assessed for eligibility. Of 64 observational studies that met the inclusion criteria, 30 (47%) investigated pain associated with musculoskeletal conditions, 24 (38%) investigated headache and 10 (16%) investigated pain associated with other conditions such as sickle cell disease and dental pain. After full text assessment, 10 of 30 papers on musculoskeletal conditions were excluded because they investigated risk of acute pain episodes rather than chronic pain symptoms (n=6), or investigated multiple conditions (n=4). The 20 included studies investigated rheumatoid arthritis (6, 30%), osteoarthritis (6, 30%), fibromyalgia (6, 30%) and low back pain (2, 10%). A total of 15 studies (75%) reported some effect of weather on chronic pain, and this was clinically significant (consistent and sufficient size of effect) in 6. Participant numbers varied from 19 to 2491. 1 study was cross-sectional and 19 longitudinal with follow ups ranging from two weeks to 3.5 years, with participants scoring their pain once to daily for 12 months. Pain was measured with a Visual Analog Scale or Numeric Rating Scale in 17 (85%). Weather conditions were retrieved from local weather stations, with most studies assuming that participants stayed in the area/city (65%) or postcode area (20%) where they lived.

In 12 (60%) studies, participants were blinded to the study hypothesis. Methods for correcting for confounders were highly variable, with 7 studies not addressing any, and the remainder addressing one or more of 32 confounding variables.

Conclusions: Methodological variability of studies investigating the relationship between weather and chronic musculoskeletal pain is high. This methodological review will inform best research practice for those investigating the relationship between the weather and chronic pain.

Acknowledgements: Mary Ingram, librarian

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.6571

AB1119 A DESCRIPTIVE STUDY OF GOUT PATIENTS IN A MULTI-ETHNIC SOCIETY

C. Chua¹, P. Cheung², A. Santosa², A. Lim², G.G. Teng². ¹Internal Medicine Residency; ²Division of Rheumatology, University Medicine Cluster, National University Health System, Singapore, Singapore

Background: Gout is a common inflammatory arthritis with rising global prevalence and health burden, especially in the Asia-Pacific regions. Ethnicity may play a significant role suggesting lifestyle and/or genetic predisposition, but studies in Asia are limited^{1,2}.

Objectives: Our study sought to assess the demographic and clinical factors of gout in the multi-ethnic Singapore and describe the burden and treatment pattern in our patients.

Methods: 282 adults with rheumatologist-diagnosed gout were recruited from rheumatology clinics of an academic medical centre in Singapore. Data on demographic and lifestyle features, medical conditions, gout severity and treatment were obtained.

Results: 282 subjects were recruited and 92.6% were men. There were 77% Chinese, 18.8% Malays and 2.5% Indians, compared to Singapore's population makeup (74%, 13% and 9% respectively). Mean age at recruitment was 52.6 years (SD 16.1) while age at gout onset was 42.5 years (SD 16.7). 34.4% received primary or no education; 67.0% were employed and 20.7% retired. 22.7% were current alcohol drinkers while 50.7% were teetotalers. 23.4% were current smokers. Mean body mass index (BMI) was 28.1kg/m² (SD 6.0), 26.6% had BMI ≥30kg/m² while 69.9% had BMI ≥25kg/m². Prevalence of hypertension was 56.7%, diabetes mellitus 18.8%, dyslipidemia 48.2% and chronic kidney disease (CKD, defined as glomerular filtration rate <60ml/min/1.73m²) 32.4%. Malays had significantly less alcohol intake (1.9%) but higher proportions of diabetes (32.1%), CKD (50.9%) and obesity (54.7%), compared with Chinese subjects (26.3%, 16.1%, 28.6% and 19.8% respectively, all Ps <0.05). Gout severity was rated moderate by 30.9% and severe in 50.4%; 69.3% suffered ≥3 attacks in 6 months. Mean SU was 477.8μmol/L (SD 130.8). 80.1% were on allopurinol. Subjects (22.3%) who achieved serum urate (SU) ≤360μmol/L, when compared to those with SU >360μmol/L, were more likely to be on urate lowering therapy (82.5% vs 60.7%, P=0.001), on higher mean allopurinol dose [337 mg/d (SD 166) vs 233 mg/d (SD 140), P<0.001] and statin (54.8% vs 33.3%, P=0.003). There were no significant differences amongst ethnicities for SU levels, gout severity and number of attacks.

Conclusions: Gout has substantial health burden in Singapore. Hypertension, dyslipidemia and obesity are more prevalent in our gout subjects compared to our population. Despite notably less alcohol intake compared with other cohorts³⁻⁵, Singapore Malays seemed to suffer higher prevalence and comorbidities of gout.

Majority of patients had moderate to severe disease but less than 25% achieved target SU levels highlighting suboptimal management of gout locally.

References:

- [1] Kuo CF, et al. Global epidemiology of gout: prevalence, incidence and risk factors. *Nat Rev Rheumatol* 2015;11(11):649–62.
- [2] Krishnan E, et al. Gout in ambulatory care settings in the United States. *J Rheumatol* 2008;35(3):498–501.
- [3] Lee CH, et al. Factors associated with gout in South Koreans: analysis using the National Health Insurance Corporation and the National Health Screening Exam databases. *Clin Rheumatol* 2013;32(6):829–37.
- [4] Cea Soriano L, et al. Contemporary epidemiology of gout in the UK general population. *Arthritis Res Ther* 2011;13(2):R39.
- [5] Vázquez-Mellado J, et al. Metabolic Syndrome and Ischemic Heart Disease in Gout. *J Clin Rheumatol* 2004;10(3):105–09.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.3950

AB1120 COMPARISON OF NON-RADIOGRAPHIC SPONDYLOARTHRITIS VERSUS ANKYLOSING SPONDYLITIS PATIENTS UNDERGOING BIOLOGICAL THERAPY

C. Cobilinschi, D. Opris-Belinski, R. Ionescu. *Santa Maria Clinical Hospital, Bucharest, Romania*

Background: Axial spondyloarthritis include non-radiographic spondyloarthritis (nr-SpA) and ankylosing spondylitis (AS); they reveal the extent of sacroiliitis assessed by conventional x-ray or MRI (1). The natural history of nr-SpA follows various evolution patterns; smoking, male gender, high levels of inflammatory markers or initial radiographic lesions are among predictor factors of progression to AS (2).

Objectives: The objective of the present study was to compare features related to progression of nr-SpA patients versus AS patients undergoing biological therapy with an anti-TNF agent.

Methods: This was an observational, cross-sectional study including 94 patients with nr-SpA and AS under continuous anti-TNF therapy for at least six months. SPSS 20.0 was used to analyze data with a P value of 0.05.

Results: Out of the selected study group, 69 patients were diagnosed with AS having a mean age of 44.8±10.8, while 25 patients had nr-SpA. Patients with nr-SpA were aged 32.1±6.6 years old and 40% of them were women, a rate significantly than in the AS group (P=0.05). Mean age at disease onset was 30.7 years for the AS subgroup versus only 23.8 years for patients with nr-SpA (P<0.001). AS patients presented a significantly higher value of the BMI compared to nr-SpA (27 versus 24.7 kg/m², P<0.001). 91% of patients had positive HLA B27 and 7.4% had a positive family history of SpA, with no significant differences between the two subgroups. A higher level of CRP was noticed in AS patients (P=0.038). In the study cohort the time interval from symptom onset to establishing a diagnosis was of 39.9±55.6 months, with a mean delay interval of 2.32 years for patients with nr-SpA and higher, of 3.5 for patients with AS (P=0.01).

Conclusions: The nr-SpA group had a considerably higher percentage of females compared to the AS subgroup. AS patients presented higher values of CRP at follow-up visits as opposed to nr-SpA patients. There were no significant differences between nr-SpA and AS patients regarding BASDAI or PtGA scores, smoking status or frequency of uveitis. The presence of HLA B27 did not differ between the two subgroups, thus it might not be a reliable predictive factor of progression.

References:

- [1] Akgul O, Ozgocmen S. Classification criteria for spondyloarthropathies. *World J Orthop*. 2011;2(12):107–115.
- [2] Wendling D. Non-radiographic spondyloarthritis: A theoretical concept or a real entity? *Jt Bone Spine* 2012;79(6):531–533. doi:10.1016/j.jbspin.2012.06.009.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.5344

AB1121 TRABECULAR BONE SCORE COMBINED WITH CLINICAL RISK FACTORS CAN PREDICT INCIDENT FRACTURE IN RHEUMATOID ARTHRITIS PATIENTS

D. Kim¹, S.-K. Cho¹, H.-R. Park¹, Y.Y. Choi², Y.-K. Sung¹. ¹Rheumatology, Hanyang University Hospital for Rheumatic Diseases; ²Nuclear medicine, Hanyang University Hospital, Seoul, Korea, Republic Of

Background: Fracture is one of the most common and important comorbidities in rheumatoid arthritis (RA) patients, especially patients who use glucocorticoids (GC). However, bone mineral density (BMD) by dual-energy x-ray absorptiometry (DXA) which is the gold standard of diagnosing and monitoring osteoporosis is not a useful tool for predicting new fracture in RA patients. Previous studies suggested the possibility of trabecular bone score (TBS) as a useful predictor for incident fracture.

Objectives: We aimed to evaluate the accuracy of TBS combined with clinical risk factors or BMD for prediction of new fracture in patients with RA.

Methods: A total of 100 female RA patients were enrolled with assessment of TBS, BMD, and clinical risk factors for fracture. During follow-up period, we